AEB and EBC Channels Now Exclusively Broadcast via Ethiosat at 57 degrees East
24.2.2021 10:50:00 EET | Business Wire | Press release
SES, the leader in global content connectivity solutions, announced today that the Ethiosat platform is now broadcasting all channels of the Association of Ethiopian Broadcasters (AEB) and the Ethiopian Broadcasting Corporation (EBC) exclusively, including many of Ethiopia’s most popular channels such as EBS, ETV News and FANA TV. The variety of lifestyle, news, sport and educational channels – more than 90 channels, out of which 21 are in high definition (HD) – from 57 degrees East, offers unmatched quality and convenience previously not experienced by Ethiopians.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223006278/en/
AEB and EBC Channels Now Exclusively Broadcast via Ethiosat at 57 degrees East (Photo: Business Wire)
In December 2020, the Ethiopian Government announced that all satellite TV channels should be moved to SES’s NSS-12 satellite so that Ethiosat can meet the local TV audiences’ desire for local and international news and entertainment channels while fuelling growth in the Ethiopian media sector.
Since then, the AEB and the EBC have had their members migrate their TV channels and broadcast them from one orbital position rather than have their viewers navigate through a multitude of foreign channels.
To support this migration, SES, through its established Elevate Installer Training programme, and supported by local partners Ethiopian Broadcasting Authority (EBA) and Ethiopian Science and Space Institution (ESSTI), has carried out daily training sessions. As a result, there are now 20,000 certified installers from all regions across Ethiopia who are equipped to help Ethiopian viewers repoint their dishes and continue to watch their favourite local channels without any disruption.
“Repointing dishes for millions of TV households across Ethiopia is not an easy feat, and it’s only possible when we have committed partners such as SES. It has taken us slightly less than two months to get our members’ channels moved to Ethiosat via SES’s satellite, and we are pleased with the progress of repointing the antennas so far,” said Amman Fissehazion, Chairman of AEB.
“We can proudly say that Ethiopians now have their own dedicated TV platform hosting exclusively all Ethiopian satellite TV channels,” said Dr Getachew Dinku Godana, Director General of EBA. “In addition to the high-quality content that this platform is offering, the strategic collaboration behind it has contributed to the creation of jobs and a sense of unity among the Ethiopian population.”
“Our commitment to our local partners in Ethiopia has never been stronger. In an incredibly short time frame, together with our local partners, we have managed to train 20,000 installers and have all AEB and EBC channels now broadcast exclusively from Ethiosat,” said Steve Collar, CEO at SES. “However, our work doesn’t stop here. Together with our local team based in Addis Ababa, we will continue to work with our local partners to repoint dishes across the country, while making sure that Ethiosat continues to host the most attractive TV offering comprising local and international channels.”
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,200 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.
About Ethiosat
Ethiosat is Ethiopia’s first dedicated TV platform to host the most popular local channels. Ethiosat’s tagline “Colour Your World” is inspired by the colourfulness of Ethiopian culture and tradition. The logo is a representation of the fact that a dedicated platform has been created for Ethiopia via satellite. You can follow Ethiosat on social media: Facebook (@ethiosatTV), Instagram(@ethiosat) or Telegram (@EthiosaTV).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223006278/en/
Contact information
Suzanne Ong
External Communications
Tel. +352 710 725 500
suzanne.ong@ses.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom